FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Heikki Frick

Research Profile

Chemicals & Drugs

Disorders

Procedures

Geographic Areas

Finland

Physiology

Disease Progression

Concepts & Ideas

Co-author Network

Publications

TOP 3
Mohamed A Elrayess; Karen E Webb; Geoff J Bellingan; Ros A Whittall; Jahangir Kabir; Emma Hawe; Mikko Syvänne; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; George J Miller; Steve E Humphries
R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events.
Philippa J Talmud; Steve Martin; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; Steve E Humphries; Mikko Syvänne
APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study.
Mikko Syvänne; Ros A Whittall; Ursula Turpeinen; Markku S Nieminen; M Heikki Frick; Y Antero Kesäniemi; Amos Pasternack; Steve E Humphries; Marja-Riitta Taskinen
Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Heikki Frick (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2004: Mohamed A Elrayess; Karen E Webb; Geoff J Bellingan; Ros A Whittall; Jahangir Kabir; Emma Hawe; Mikko Syvänne; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; George J Miller; Steve E Humphries
R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events.
Atherosclerosis 2004;177(1):127-35.
2004: Philippa J Talmud; Steve Martin; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; Steve E Humphries; Mikko Syvänne
APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study.
Journal of lipid research 2004;45(4):750-6.
2004: Mikko Syvänne; Ros A Whittall; Ursula Turpeinen; Markku S Nieminen; M Heikki Frick; Y Antero Kesäniemi; Amos Pasternack; Steve E Humphries; Marja-Riitta Taskinen
Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis.
Atherosclerosis 2004;172(2):267-72.
2003: Mohamed A Elrayess; Karen E Webb; David M Flavell; Mikko Syvänne; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; J Wouter Jukema; John J P Kastelein; Aeilko H Zwinderman; Steve E Humphries
A novel functional polymorphism in the PECAM-1 gene (53G>A) is associated with progression of atherosclerosis in the LOCAT and REGRESS studies.
Atherosclerosis 2003;168(1):131-8.
2003: Philippa J Talmud; Steve Martin; George Steiner; David M Flavell; David Whitehouse; Sylvia Nagl; Richard Jackson; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; Steve E Humphries; Mikko Syvänne
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(4):644-9.
2002: David M Flavell; Yalda Jamshidi; Emma Hawe; Inés Pineda Torra; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; Bart Staels; George Miller; Steve E Humphries; Philippa J Talmud; Mikko Syvänne
Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease.
Circulation 2002;105(12):1440-5.
2001: Fredrik Karpe; Marja-Riitta Taskinen; Markku S Nieminen; M Heikki Frick; Y Antero Kesäniemi; Amos Pasternack; Anders Hamsten; Mikko Syvänne
Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment.
Atherosclerosis 2001;157(1):181-7.
2000: Anders Hamsten; Mikko Syvänne; Angela Silveira; Le Luong; Markku S Nieminen; Steve E Humphries; M Heikki Frick; Marja-Riitta Taskinen
Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
Thrombosis and haemostasis 2000;83(3):397-403.
1999: Heikki V Huikuri; Vesa Jokinen; Mikko Syvänne; Markku S Nieminen; K E Juhani Airaksinen; Markku Ikäheimo; Juhani Koistinen; Heikki Kauma; Antero Kesäniemi; Silja Majahalme; Kari Niemelä; M Heikki Frick
Heart rate variability and progression of coronary atherosclerosis.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(8):1979-85.
1998: Mikko Syvänne; Markku S Nieminen; M Heikki Frick; Heikki Kauma; Silja Majahalme; Vesa Virtanen; Y Antero Kesäniemi; Amos Pasternack; Christian Ehnholm; Marja-Riitta Taskinen
Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
Circulation 1998;98(19):1993-9.
1998: Steve E Humphries; Le Luong; Philippa J Talmud; M Heikki Frick; Y Antero Kesäniemi; Amos Pasternack; Marja-Riitta Taskinen; Mikko Syvänne
The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial.
Atherosclerosis 1998;139(1):49-56.
1998: Esa Tahvanainen; M Syvanne; M Heikki Frick; S Murtomaki-Repo; Marjatta Antikainen; Y A Kesaniemi; Heikki Kauma; A Pasternak; Marja-Riitta Taskinen; Christian Ehnholm
Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study Invsestigators.
The Journal of clinical investigation 1998;101(5):956-60.
1997: M Heikki Frick; Mikko Syvänne; Markku S Nieminen; Heikki Kauma; Silja Majahalme; Vesa Virtanen; Y Antero Kesäniemi; Amos Pasternack; Marja-Riitta Taskinen
Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
Circulation 1997;96(7):2137-43.
1997: Mikko Syvänne; Marja-Riitta Taskinen; V Manninen; Y Antero Kesäniemi; Amos Pasternack; J W Nawrocki; H Haber; M Heikki Frick
A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. Lopid Coronary Angiography Trial.
Controlled clinical trials 1997;18(1):93-119.
1995: Matti Mänttäri; Leena Tenkanen; Vesa Manninen; Tiina Alikoski; M Heikki Frick
Antihypertensive therapy in dyslipidemic men. Effects on coronary heart disease incidence and total mortality.
Hypertension 1995;25(1):47-52.
1994: Mikko Syvänne; Markku S Nieminen; M Heikki Frick
Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery. A validation study.
International journal of cardiac imaging 1994;10(4):243-52.
1994: Matti Mänttäri; Vesa Manninen; J K Huttunen; T Palosuo; Christian Ehnholm; OP Heinonen; M Heikki Frick
Serum ferritin and ceruloplasmin as coronary risk factors.
European heart journal 1994;15(12):1599-603.
1994: A Hautanen; Matti Mänttäri; Vesa Manninen; Leena Tenkanen; J K Huttunen; M Heikki Frick; Herman Adlercreutz
Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study.
Atherosclerosis 1994;105(2):191-200.
1994: OP Heinonen; J K Huttunen; Vesa Manninen; Matti Mänttäri; Petri Koskinen; Leena Tenkanen; M Heikki Frick
The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up.
Journal of internal medicine 1994;235(1):41-9.
1994: J K Huttunen; OP Heinonen; Vesa Manninen; Petri Koskinen; T Hakulinen; L Teppo; Matti Mänttäri; M Heikki Frick
The Helsinki Heart Study: an 8.5-year safety and mortality follow-up.
Journal of internal medicine 1994;235(1):31-9.
1993: A Hautanen; Matti Mänttäri; M Kupari; S Sarna; Vesa Manninen; M Heikki Frick; Herman Adlercreutz
Cigarette smoking is associated with elevated adrenal androgen response to adrenocorticotropin.
The Journal of steroid biochemistry and molecular biology 1993;46(2):245-51.
1993: Matti Mänttäri; K Javela; Petri Koskinen; J Pikkarainen; Vesa Manninen; J K Huttunen; M Heikki Frick
Seasonal variation in high density lipoprotein cholesterol.
Atherosclerosis 1993;100(2):257-65.
1993: M Heikki Frick; OP Heinonen; J K Huttunen; Petri Koskinen; Matti Mänttäri; Vesa Manninen
Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population.
Annals of medicine 1993;25(1):41-5.
1992: Petri Koskinen; Matti Mänttäri; Vesa Manninen; J K Huttunen; OP Heinonen; M Heikki Frick
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
Diabetes care 1992;15(7):820-5.
1992: A Hautanen; Matti Mänttäri; Vesa Manninen; M Heikki Frick; Herman Adlercreutz
Effects of gemfibrozil treatment on serum levels of androstanediol glucuronide and adrenal androgens.
The Journal of steroid biochemistry and molecular biology 1992;42(3-4):433-4.
1992: Matti Mänttäri; Vesa Manninen; Petri Koskinen; J K Huttunen; E Oksanen; Leena Tenkanen; OP Heinonen; M Heikki Frick
Leukocytes as a coronary risk factor in a dyslipidemic male population.
American heart journal 1992;123(4 Pt 1):873-7.
1992: Pekka Saikku; Maija Leinonen; Leena Tenkanen; E Linnanmäki; M R Ekman; Vesa Manninen; Matti Mänttäri; M Heikki Frick; J K Huttunen
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.
Annals of internal medicine 1992;116(4):273-8.
1992: T J Pellinen; K Lukkala; S Sundberg; J Heikkilä; M Heikki Frick
Efficacy of conventional and sustained-release verapamil in stable angina pectoris.
Annals of medicine 1992;24(1):49-53.
1992: Vesa Manninen; Leena Tenkanen; Petri Koskinen; J K Huttunen; Matti Mänttäri; OP Heinonen; M Heikki Frick
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
Circulation 1992;85(1):37-45.
1991: Heikki O Tikkanen; Matti Härkönen; Hannu Näveri; Esa Hämäläinen; R Elovainio; S Sarna; M Heikki Frick
Relationship of skeletal muscle fiber type to serum high density lipoprotein cholesterol and apolipoprotein A-I levels.
Atherosclerosis 1991;90(1):49-57.
1991: J K Huttunen; Vesa Manninen; Matti Mänttäri; Petri Koskinen; M Romo; Leena Tenkanen; OP Heinonen; M Heikki Frick
The Helsinki Heart Study: central findings and clinical implications.
Annals of medicine 1991;23(2):155-9.
1991: T J Pellinen; Kari S Virtanen; Lauri Toivonen; J Heikkilä; Pauli E Hekali; M Heikki Frick
Coronary collateral circulation.
Clinical cardiology 1991;14(2):111-8.
1990: Matti Mänttäri; J K Huttunen; Petri Koskinen; Vesa Manninen; Leena Tenkanen; OP Heinonen; M Heikki Frick
Lipoproteins and coronary heart disease in the Helsinki Heart Study.
European heart journal 1990;11 Suppl H():26-31.
1990: Matti Mänttäri; M Romo; Vesa Manninen; Petri Koskinen; J K Huttunen; OP Heinonen; M Heikki Frick
Reduction in Q wave myocardial infarctions with gemfibrozil in the Helsinki Heart Study.
American heart journal 1990;119(5):991-5.
1990: Matti Mänttäri; Petri Koskinen; Vesa Manninen; J K Huttunen; M Heikki Frick; E A Nikkilä
Effect of gemfibrozil on the concentration and composition of serum lipoproteins. A controlled study with special reference to initial triglyceride levels.
Atherosclerosis 1990;81(1):11-7.
1990: M Heikki Frick; Vesa Manninen; J K Huttunen; OP Heinonen; Leena Tenkanen; Matti Mänttäri
HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study.
Drugs 1990;40 Suppl 1():7-12.
1989: Vesa Manninen; J K Huttunen; OP Heinonen; Leena Tenkanen; M Heikki Frick
Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study.
The American journal of cardiology 1989;63(16):42H-47H.
1989: K S Virtanen; S Mattila; A Järvinen; M Heikki Frick
Angiographic findings in patients exhibiting ischemia after oral dipyridamole.
International journal of cardiology 1989;23(1):33-6.
1989: M Heikki Frick; D McGibney; H M Tyler
A dose-response study of amlodipine in mild to moderate hypertension.
Journal of internal medicine 1989;225(2):101-5.
1988: Vesa Manninen; M O Elo; M Heikki Frick; K Haapa; OP Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; Petri Koskinen
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
JAMA : the journal of the American Medical Association 1988;260(5):641-51.
1988: J K Huttunen; M Heikki Frick; OP Heinonen; P Heinsalmi; Vesa Manninen; Matti Mänttäri; M Romo
Helsinki Heart Study. New perspectives in the prevention of coronary heart disease.
Drugs 1988;36 Suppl 3():32-6.
1988: M Heikki Frick; D McGibney; H M Tyler
Amlodipine: a double-blind evaluation of the dose-response relationship in mild to moderate hypertension.
Journal of cardiovascular pharmacology 1988;12 Suppl 7():S76-8.
1987: M Heikki Frick; O Elo; K Haapa; OP Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; Petri Koskinen; Vesa Manninen
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
The New England journal of medicine 1987;317(20):1237-45.
1987: Matti Mänttäri; O Elo; M Heikki Frick; K Haapa; OP Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; Petri Koskinen
The Helsinki Heart Study: basic design and randomization procedure.
European heart journal 1987;8 Suppl I():1-29.
1986: T J Pellinen; Kari S Virtanen; M Valle; M Heikki Frick
Studies on ergometer exercise testing. II. Effect of previous myocardial infarction, digoxin, and beta-blockade on exercise electrocardiography.
Clinical cardiology 1986;9(10):499-507.
1986: T J Pellinen; Kari S Virtanen; M Valle; M Heikki Frick
Studies on ergometer exercise testing. I. Significance of the type of ST-segment response, sex, and chest pain.
Clinical cardiology 1986;9(7):315-22.